Menu
Currency
GWAS Study

Improving lithium dose prediction using population pharmacokinetics and pharmacogenomics: a cohort genome-wide association study in Sweden.

Millischer V, Matheson GJ, Bergen SE et al.

35569502 PubMed ID
GWAS Study Type
2190 Participants
53 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

MV
Millischer V
MG
Matheson GJ
BS
Bergen SE
CB
Coombes BJ
PK
Ponzer K
WF
Wikström F
JK
Jagiello K
LM
Lundberg M
SP
Stenvinkel P
BJ
Biernacka JM
BO
Breuer O
ML
Martinsson L
LM
Landén M
BL
Backlund L
LC
Lavebratt C
SM
Schalling M
Chapter II

Abstract

Summary of the research findings

Lithium is the most effective treatment for bipolar disorder, resulting in strong suicide prevention effects. The therapeutic range of lithium, however, is narrow and treatment initiation requires individual titration to address inter-individual variability. We aimed to improve lithium dose prediction using clinical and genomic data.

2,190 European or unknown individuals

Chapter III

Study Statistics

Key metrics and study information

2190
Total Participants
GWAS
Study Type
No
Replicated
European, NR
Ancestry
Sweden
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.